The predictions come after Abbott announced break up its current company into two separate firms, reversing its previous trend of diversification.
.../...Roche, Bayer and Merck are the three firms most likely to go for an acquisition according to analysts, as all three need to shore up their drug portfolios. So far, all three firms have declined to comment on the speculation.
(Más)
Entradas
No hay comentarios:
Publicar un comentario